Table 4.

Baseline Characteristics of the Study Groups

	rhTSH (n=15)	THW (n=41)	p-Value
Age (years)	62.4±12.6	48.8±18.2	0.010a
Sex	73.3% females	48.8% females	0.090
	26.7% males	51.2% males
T (cm)	4.0±0.75	4.3±0.46	0.717
% of patients with extrathyroidal extension	35.7%	45.5%	0.387
% of patients with pulmonary metastases countable micronodular	13.3%	14.6%	0.637
% of patients with pulmonary metastases countable macronodular	13.3%	14.6%	0.637
% of patients with micronodular multiple pulmonary metastases	66.7%	63.4%	0.541
% of patients with bone metastases	53.3%	29.3%	0.090
% of patients with a-typical metastases (brain, liver, kidney)	13.3%	12.2%	0.612
The sum of max diameter of target lesions (cm)	6.4±2.3	4.8±4.2	0.407
Baseline nonstimulated Tg (ng/mL) before the treatment	6995±15,879	5544±22,163	0.372

^aStatistically significant difference.

rhTSH, recombinant human thyrotropin; THW, thyroid hormone withdrawal.